We have previously demonstrated the presence of gonadotropinreleasing hormone (Gn-RH) messenger ribonucleic acid (mRNA) in epithelial ovarian carcinoma. In this study, the expression of Gn-RH receptor (Gn-RHR) was investigated in human ovarian carcinoma and human ovarian carcinoma cell line. Gn-RHR was determined by [JH 1Gn-RH binding assay. Gn-RHR mRNA was determined by reverse transcription-polymerase chain reaction using oligonucleotide primers synthesized based on published human Gn-RHR sequence.
Ovarian cancer is one of the most difficult diseases to diagnose and treat, in women. There are no satisfactory investigations to determine whether ovarian carcinoma would respond to endocrine therapy. Recent evidence suggests that gonadotropin-releasing hormone (Gn-RH) might act as an autocrine regulator of proliferation of certain hormone-responsive tumours.':" Human epithelial ovarian carcinoma has been shown to express Gn-RH messenger ribonucleic acid (mRNA), produce Gn-RH,7 and have specific binding sites for Gn_RH. [8] [9] [10] Gn-RH analogues have been used in the treatment of the sex steroid-sensitive cancers including ovarian carcinoma.J " Growth of ovarian carcinoma is inhibited by Gn-RH analogues, and clinical studies have indicated beneficial effects even in metastatic tumours. [11] [12] [13] [14] [15] [16] [17] Gn-RH agonists can also suppress the growth of ovarian carcinoma cells in vitro. 18 -20 These circumstantial findings suggest direct regulatory effects of Gn-RH on tumour growth. Thus, the demonstration of Gn-RH receptors on the tumour Correspondence: Atsushi Imai MD, PhD. 550 may better predict hormonal dependency, and help towards an effective hormonal treatment. We have therefore examined human ovarian carcinoma for the presence of Gn-RH receptor (Gn-RHR) and its mRNA. [3,4- 
MATERIALS AND METHODS

Materials
Tissue collection and cell cultures
Ovarian tumours and normal tissues (ovary and endometrium) were placed in ice-cold phosphatebuffered saline (PBS) immediately after surgical removal and representative portions were excised for frozen section. As far as possible carcinoma tissue was carefully separated from normal ovarian tissue. Carcinoma samples were prepared from a firm polypoid mass growing from the tumour. Tissue samples were washed, and immediately used or stored in liquid nitrogen. Human ovarian adenocarcinoma cell line SK-OV-3 was obtained from American Type Culture Collection. The cells were grown at 37°C in an appropriate medium containing 10070 fetal bovine serum in 150 ern? flask in a humidified atmosphere of 5% CO 2-95% air.
Preparation of plasma membrane Plasma membrane fraction from these tumours and cell pellets were prepared by the procedure described before. 2 l ,22 The isolated plasma membranes were finally resuspended in lysis buffer (I mmollL ethyleneglycol tetraacetic acid (EGT A), I mmollL dithiothreitol, 10 mmollL Tris, pH 7,4) and immediately submitted to the following experiments. 5' -nucleotidase was measured as a marker for plasma membrane." Protein was determined according to the method of Lowry et al. 24 using bovine serum albumin (BSA) as a standard. The specific activity of 5' -nucleotidase was sevenfold higher in the plasma membrane fraction, as compared to the homogenate (10'5 compared to 1·5 iLmollmg protein/h).
Gn-RH binding assay
Gn-RH binding sites in the plasma membrane preparation were determined by incubating aliquots (0'1 mL) containing approximately 50 iLg protein of plasma membrane in triplicate with [3H] Gn-RH (37 MBq) in the presence of unlabelled Gn-RH (concentration range of 1-30xlO-9moIlL). A 200-fold excess of unlabelled Gn-RH was added to paired samples for determination of non-specific binding. Incubations were carried out at 4°C for 16 h, after which the bound 3H was trapped to a membrane filter, and the filter washed and counted. Specific binding of [3H] Gn-RH was calculated by subtracting non-specific binding from total binding. Non-specific binding was approximately 20-30% of total binding and relatively constant. The dissociation constant (Kd) of [3H] Gn-RH binding was determined by Scatchard plot. 25 
RNA isolation
Total RNA was extracted from tissues or cell pellets according to the procedure of Chromcynski Gn-RH receptor in ovarian carcinoma 551 and Sacchi." Briefly, the specimens were homogenized in guanidium thiocyanate followed by acid phenollchloroform extraction, precipitated with isopropanol and reextracted with guanidium thiocyanate and reprecipitated with isopropanol. Samples were enriched for poly(A) + RNA by purification on an oligo(dT) cellulose column.F according to the manufacturer's instructions.
Reverse transcription (RT) and polymerase chain reaction (peR) amplification A random primed complementary DNA (cDNA) library was prepared from 200 ng of poly(A) RNA using the Moloney murine leukemia reverse transcriptase under the conditions recommended by the supplier. The cDNA (25 iLL) was diluted with 300 iLL water, heat-denatured at 95°C for 5 min, and quickly chilled on ice.
The cDNA (l iLL) was amplified in a 50 iLL reaction containing 10 mmollL Tris-HCI (pH 8· 3), 50 mmollL KCI, 2 mmollL MgCI 2 , 50 iLmollL each deoxynucleotide trisphosphates, and 1·25 U Taq polymerase, and 0·5 iLmollL pnrners." The sequences of oligonucleotide primers, synthesized according to the published human Gn-RHR sequence." were as follows: The predicted fragments amplified by PCR using primers a and b or primers c and d were 319 base pairs (bp) and 997 bp, respectively. We carried out 35 cycles of amplification; denaturation at 94°C for 2 min, annealing at 55°C for 1 min, and extension at noc for 2 min, followed by a final extension for 10 min at noc. The DNA product (10 iLL) was electrophoresed on 2% agarose gel, and bands were visualized by ethidium bromide staining on a UV transilluminator.
Sequence analysis
Sequence analysis of the PCR products was carried out manually by the dideoxy chain termination method.t? using Sequenase II according to the manufacturer's protocol.
RESULTS
Gn-RH binding to plasma membrane Five cases of mucinous cystadenocarcinoma and one case of serous cystadenocarcinoma were evaluated for [3H] Gn-RH binding. All specimens tested showed specific binding sites and the specific binding was reproducible and only one class of receptor was found. The binding characteristics of a mucinous cystadenocarcinoma N Q .. and a serous cystadenocarcinoma are shown in Fig. 1 . Characteristics of Gn-RH binding in these specimens are given in Table 1 . High affinity binding could also be demonstrated in normal ovary and endometrium.
Gn-RHR mRNA PCR amplification of Gn-RHR cDNA from mucinous cystadenocarcinoma (n = 4), serous cystadenocarcinoma (n = I), SK-OY-3 cell line, white blood cells (n = 1) and normal ovary (n = 1) was conducted with two sets of oligonucleotide primers as described under 'Methods'. All ovarian carcinomas tested, normal ovary and endomedrium which was used on a positive control yielded expected 319-and 997base pair products, while there was no product from white blood cells. Representative data from these experiments are given in Fig. 2 . Human ovarian adenocarcinoma cell line SK-OY-3 also gave a predominant product identical to that obtained in tumour tissues (Fig. 2) .
By sequence analysis, the product was also observed to have homology to the consensus sequence.
DISCUSSION
Previous in vivo and in vitro results support the view that Gn-RH analogues have a direct effect on some hormone-dependent tumours including ovarian carcinoma. 1-6 Specific binding sites for Gn-RH have been detected in membranes isolated from human epithelial ovarian carcinorna.v '? The results presented here confirm these findings, and extend these observations by demonstrating that ovarian tumour expresses Gn-RHR mRNA. In our study, homologeous displacement assays showed that in plasma membrane from ovarian carcinoma, Gn-RH bound to one class of specific, saturable, noncooperative binding sites (Kd= 15·3±8·08x 1O-9moIlL) in a manner similar to other Gn-RH target tissues. In contrast to the high affinity binding in this study, Emons et al. 8 demonstrated a low affinity binding site (Kd= 1·4 x 10-' mollL) in membranes from ovarian epithelial carcinoma. Low affinity binding sites for Gn-RH with Kd of the order of 10-'-10 -6 mollL has been described in breast cancer,31.32 prostate cancer,33.34 pancreatic cancer.v and placenta. 36 • 37 On the other hand, there are other studies which report high affinity binding sites in prostatic cancer," ovary,38.39 and placenta." The reason for these discrepancies is not clear. The difference may be due to characteristics of respective tumour tissues or cellular variability of the binding protein.
The demonstration of Gn-RH mRNA by PCR amplification study further authenticates the presence and production of Gn-RHR in these tissues. PCR amplification generated products identical to that from the pituitary,29 a well established site of Gn-RHR expression. The amplification products using two separate sets of primers had the predicted sizes, and sequence analysis showed homology to the consensus sequence of Gn-RHR. The sizes of the Gn-RH receptor in ovarian carcinoma 553 amplification products ruled out the possibility that they could have resulted from amplification of genomic DNA. The possibility that our results might be accounted for by cross-tissue contamination from normal ovarian tissue, seemed highly unlikely as we have previously demonstrated the presence of a Gn-RH and its mRNA in epithelial ovarian carcinoma but not in normal ovary, under identical experimental conditions including the preparation of sample. 7
The demonstration of Gn-RHR mRNA in cell line (SK-OV-3) further confirms that mRNA are coming from the tumour cells rather than from normal ovary. Although the demonstration of Gn-RHR expression strongly raises the possibility that Gn-RH may play an autocrine regulatory role in the growth of ovarian carcinoma, the functional importance of the Gn-RHR is not clear at present. More recently, the Gn-RH binding site has been shown to be coupled to phospholipase C-mediated phosphoinositide hydrolysis which is known to regulate cellular proliferarion.!" in the pituitary" and granulosa cells. 42 The chronic occupancy of Gn-RH receptor by Gn-RH analogues induces desensitization and/or downregulation of tumour phospholipase C with a consequent decline of tumour growth (Imai et al., unpublished observations), in an analogous manner to the action of Gn-RH analogue on anterior pituitary. We suggest that this is the most plausible explanation for the efficacy of Gn-RH analogue treatment of ovarian cancer.
Because the overall results of traditional treatment of ovarian cancer are stiD disappointing, the detection of Gn-RH and/or its receptor, in the tumour, might be a first step towards an effective hormonal treatment with Gn-RH analogues.
